JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 2.62 HKD 1.55%
Market Cap: 1.1B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
JW (Cayman) Therapeutics Co Ltd

There are no price targets for JW (Cayman) Therapeutics Co Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
JW (Cayman) Therapeutics Co Ltd Competitors:
Price Targets
300122
Chongqing Zhifei Biological Products Co Ltd
47% Upside
ALDX
Aldeyra Therapeutics Inc
187% Upside
FYB
Formycon AG
117% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
16% Downside
300122
Chongqing Zhifei Biological Products Co Ltd
47% Upside
ALDX
Aldeyra Therapeutics Inc
187% Upside
FYB
Formycon AG
117% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
16% Downside
LEGN
Legend Biotech Corp
133% Upside
KRYS
Krystal Biotech Inc
52% Upside
VITR
Vitrolife AB
61% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
JW (Cayman) Therapeutics Co Ltd

The compound annual growth rate of JW (Cayman) Therapeutics Co Ltd's revenue for the next 3 years is 76%.

N/A
Past Growth
76%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
JW (Cayman) Therapeutics Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
JW (Cayman) Therapeutics Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JW (Cayman) Therapeutics Co Ltd's stock price target?
Not Available

JW (Cayman) Therapeutics Co Ltd doesn't have any price targets made by Wall Street professionals.

What is JW (Cayman) Therapeutics Co Ltd's Revenue forecast?
Projected CAGR
76%

The compound annual growth rate of JW (Cayman) Therapeutics Co Ltd's revenue for the next 3 years is 76%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.